Q: What is Cimzia used for?

Cimzia is used to treat the following conditions: Crohn's disease Rheumatoid arthritis Psoriatic arthritis Others

Q: How does Cimzia work?

Targeting TNF-Alpha Cimzia belongs to a class of drugs called tumor necrosis factor (TNF) blockers. TNF is a protein produced by the immune system that plays a key role in causing inflammation. In people with certain autoimmune diseases, the body produces too much TNF, which leads to pain, swelling, and damage to healthy tissues. Neutralizing Inflammation The medication works by binding directly to TNF-alpha proteins in the body. By attaching to these proteins, Cimzia prevents them from interacting with cell receptors that trigger the inflammatory response. This process helps to calm the overactive immune system and reduce the symptoms associated with conditions like rheumatoid arthritis, Crohn's disease, and plaque psoriasis. Extended Action Cimzia is a pegylated antibody fragment. This means it has been chemically modified with polyethylene glycol (PEG), which allows the medication to remain active in the bloodstream for a longer duration. This design helps maintain a consistent level of the drug in the body to provide ongoing relief from inflammation.

Q: What are the active ingredients in Cimzia?

The active ingredient in Cimzia is certolizumab pegol .

Q: What are the side effects of Cimzia?

Common side effects of Cimzia may include: upper respiratory tract infection rash urinary tract infection and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Cimzia?

Cimzia belongs to the TNF inhibitor drug class.

Q: Is Cimzia safe during pregnancy and breastfeeding?

Pregnancy Data from clinical studies and pregnancy registries suggest that Cimzia does not increase the risk of major birth defects, miscarriage, or adverse outcomes for the mother or the baby. Unlike many other medications in its class, Cimzia lacks a specific component called the Fc region, which is typically required for a drug to cross the placenta in significant amounts. As a result, there is minimal to no transfer of the medication from the mother to the fetus. If you are pregnant or planning to become pregnant, it is important to discuss your treatment plan with your doctor. Healthcare providers may encourage participation in a pregnancy exposure registry to monitor the health of both the mother and the baby during and after pregnancy. Breastfeeding Cimzia is excreted into human breast milk, but the levels are very low. Because the medication is a large protein molecule, it is likely broken down in the infant's digestive tract, meaning very little of the drug is expected to be absorbed by a breastfeeding child. Research has not shown an increased risk of side effects in infants exposed to the drug through breast milk. The decision to breastfeed while taking Cimzia should be made in consultation with a healthcare provider, weighing the developmental and health benefits of breastfeeding against the mother's clinical need for the medication.

Q: What forms and strengths does Cimzia come in?

Available Forms Cimzia is administered as an injection under the skin (subcutaneous injection). It is supplied in the following formats: Prefilled Syringe: A single-dose, disposable syringe containing a liquid solution. This form is designed for ease of use and may be used for self-injection after proper training. Lyophilized Powder: A single-dose vial containing a concentrated powder. This form must be reconstituted (mixed) with sterile water by a healthcare professional before it can be injected. Both forms are intended for single use only. Any unused portion remaining in the vial or syringe should be discarded according to medical guidelines.

Q: What is the FDA approval status of Cimzia?

FDA Approval and Indications Cimzia was first approved by the U.S. Food and Drug Administration (FDA) in April 2008. It is classified as a tumor necrosis factor (TNF) blocker. The FDA has approved Cimzia for the treatment of the following conditions in adults: Crohn's disease (for reducing signs and symptoms and maintaining clinical response in patients with moderate to severe disease) Moderate to severe rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis Non-radiographic axial spondyloarthritis with objective signs of inflammation Moderate to severe plaque psoriasis Boxed Warning The FDA requires a boxed warning for Cimzia due to the following serious safety risks: Serious Infections: Patients treated with Cimzia are at increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial sepsis, and invasive fungal infections (such as histoplasmosis). Patients should be tested for latent TB before starting treatment and monitored for active TB during therapy. Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. While Cimzia is not approved for use in pediatric patients, this risk is noted for the drug class. Cases of non-melanoma skin cancer and Hodgkin's lymphoma have also been reported in adults using these medications. Regulatory Requirements Cimzia is available only by prescription. While it does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA requires that a Medication Guide be provided to every patient to explain the potential risks and benefits associated with the treatment.

Question 1

What is Cimzia?

Accepted Answer

Cimzia is a medication that belongs to a class of drugs known as tumor necrosis factor (TNF) blockers. It works by targeting and binding to a specific protein in the body called TNF-alpha, which is a primary driver of inflammation.

By blocking this protein, the medication helps to reduce the body's inflammatory response. This action is intended to manage symptoms and limit the damage caused by an overactive immune system.

Question 2

What is Cimzia used for?

Accepted Answer

Cimzia is used to treat the following conditions:

Crohn's disease
Rheumatoid arthritis
Psoriatic arthritis
Others

Question 3

How does Cimzia work?

Accepted Answer

Targeting TNF-Alpha

Cimzia belongs to a class of drugs called tumor necrosis factor (TNF) blockers. TNF is a protein produced by the immune system that plays a key role in causing inflammation. In people with certain autoimmune diseases, the body produces too much TNF, which leads to pain, swelling, and damage to healthy tissues.

Neutralizing Inflammation

The medication works by binding directly to TNF-alpha proteins in the body. By attaching to these proteins, Cimzia prevents them from interacting with cell receptors that trigger the inflammatory response. This process helps to calm the overactive immune system and reduce the symptoms associated with conditions like rheumatoid arthritis, Crohn's disease, and plaque psoriasis.

Extended Action

Cimzia is a pegylated antibody fragment. This means it has been chemically modified with polyethylene glycol (PEG), which allows the medication to remain active in the bloodstream for a longer duration. This design helps maintain a consistent level of the drug in the body to provide ongoing relief from inflammation.

Question 4

What are the active ingredients in Cimzia?

Accepted Answer

The active ingredient in Cimzia is certolizumab pegol.

Question 5

What are the side effects of Cimzia?

Accepted Answer

Common side effects of Cimzia may include:

upper respiratory tract infection
rash
urinary tract infection
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Cimzia?

Accepted Answer

Cimzia belongs to the TNF inhibitor drug class.

Question 7

What is the dosage of Cimzia and how do I take it?

Accepted Answer

How it is Administered

Cimzia is given by subcutaneous injection, which means it is injected into the fatty tissue just under the skin. Common injection sites include the front of the thighs or the abdomen. It is important to rotate the injection site each time a dose is given, avoiding areas where the skin is tender, bruised, red, or hard.

Self-Injection

A healthcare provider may administer the initial doses. After receiving proper training, you or a caregiver may be able to perform the injections at home. Do not attempt to self-inject until you have been shown the correct technique by a healthcare professional.

Preparation and Storage

Store the medication in the refrigerator and keep it in its original carton to protect it from light. Do not freeze.
Before injecting, remove the medication from the refrigerator and allow it to reach room temperature naturally. Do not use external heat sources like a microwave or hot water to warm it.
Do not shake the syringe or vial.
Check the liquid before use; it should be clear to opalescent and colorless to pale yellow. Do not use the medication if it is cloudy, discolored, or contains large particles.

Missed Doses

If you miss a dose of Cimzia, contact your healthcare provider or pharmacist for instructions on when to schedule your next injection. It is important to stay on the schedule prescribed by your doctor. Do not use extra medication to make up for a missed dose.

Question 8

Is Cimzia safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Data from clinical studies and pregnancy registries suggest that Cimzia does not increase the risk of major birth defects, miscarriage, or adverse outcomes for the mother or the baby. Unlike many other medications in its class, Cimzia lacks a specific component called the Fc region, which is typically required for a drug to cross the placenta in significant amounts. As a result, there is minimal to no transfer of the medication from the mother to the fetus.

If you are pregnant or planning to become pregnant, it is important to discuss your treatment plan with your doctor. Healthcare providers may encourage participation in a pregnancy exposure registry to monitor the health of both the mother and the baby during and after pregnancy.

Breastfeeding

Cimzia is excreted into human breast milk, but the levels are very low. Because the medication is a large protein molecule, it is likely broken down in the infant's digestive tract, meaning very little of the drug is expected to be absorbed by a breastfeeding child. Research has not shown an increased risk of side effects in infants exposed to the drug through breast milk.

The decision to breastfeed while taking Cimzia should be made in consultation with a healthcare provider, weighing the developmental and health benefits of breastfeeding against the mother's clinical need for the medication.

Question 9

What forms and strengths does Cimzia come in?

Accepted Answer

Available Forms

Cimzia is administered as an injection under the skin (subcutaneous injection). It is supplied in the following formats:

Prefilled Syringe: A single-dose, disposable syringe containing a liquid solution. This form is designed for ease of use and may be used for self-injection after proper training.
Lyophilized Powder: A single-dose vial containing a concentrated powder. This form must be reconstituted (mixed) with sterile water by a healthcare professional before it can be injected.

Both forms are intended for single use only. Any unused portion remaining in the vial or syringe should be discarded according to medical guidelines.

Question 10

What is the FDA approval status of Cimzia?

Accepted Answer

FDA Approval and Indications

Cimzia was first approved by the U.S. Food and Drug Administration (FDA) in April 2008. It is classified as a tumor necrosis factor (TNF) blocker. The FDA has approved Cimzia for the treatment of the following conditions in adults:

Crohn's disease (for reducing signs and symptoms and maintaining clinical response in patients with moderate to severe disease)
Moderate to severe rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
Non-radiographic axial spondyloarthritis with objective signs of inflammation
Moderate to severe plaque psoriasis

Boxed Warning

The FDA requires a boxed warning for Cimzia due to the following serious safety risks:

Serious Infections: Patients treated with Cimzia are at increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial sepsis, and invasive fungal infections (such as histoplasmosis). Patients should be tested for latent TB before starting treatment and monitored for active TB during therapy.
Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. While Cimzia is not approved for use in pediatric patients, this risk is noted for the drug class. Cases of non-melanoma skin cancer and Hodgkin's lymphoma have also been reported in adults using these medications.

Regulatory Requirements

Cimzia is available only by prescription. While it does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA requires that a Medication Guide be provided to every patient to explain the potential risks and benefits associated with the treatment.

Question 11

What should I know about Cimzia and cost?

Accepted Answer

Insurance and Coverage

The out-of-pocket cost for Cimzia is largely determined by your health insurance plan. As a biologic medication, it is often placed in a higher cost-sharing tier on insurance formularies. Your expenses may include copayments, coinsurance, or meeting a deductible before coverage begins.

Specialty Pharmacy Requirements

Cimzia is typically dispensed through a specialty pharmacy rather than a standard retail pharmacy. Specialty pharmacies are equipped to handle high-cost medications that require specific storage conditions, such as refrigeration. These pharmacies often work directly with insurance providers to coordinate coverage and delivery.

Financial Assistance Options

There are several programs that may help reduce the cost of Cimzia for eligible patients:

Copay Savings Cards: These may be available for individuals with commercial insurance to help lower monthly out-of-pocket expenses.
Patient Assistance Programs: These programs may provide the medication at a reduced cost or for free to individuals who meet certain income requirements and lack adequate insurance coverage.

For those with Medicare, coverage depends on how the drug is administered. If it is injected by a healthcare professional in a clinic, it may be covered under Medicare Part B. If it is self-injected at home, it is typically covered under a Medicare Part D prescription drug plan.

Cimzia

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Cimzia

Hospitals.net Disclosure